TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Japanese shares end higher on Wall St boost, airlines shine

12/23/2021 | 01:44am EDT

TOKYO, Dec 23 (Reuters) - Japanese shares ended higher on Thursday, tracking a strong overnight finish on Wall Street, while positive data from a South African study on the Omicron COVID-19 variant lifted airline stocks.

The Nikkei share average jumped 0.83% to close at 28,798.37, marking its third straight session of gain. The broader Topix rose 0.91% to 1,989.43.

"Some positive news overseas about the Omicron has erased concerns over the impact of the virus even as Japan reported the first community infections of the virus," said Seiichi Suzuki, chief equity market analyst at Tokai Tokyo Research Institute.

Wall Street staged a broad rally overnight on upbeat economic data and a South African study that suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus Delta.

In Japan, airline shares advanced 2.24% on hopes that people would keep travelling despite news of Japan's first instance of community spread infection from the Omicron.

Commodities-related shares gained as oil prices rose, with oil and coal explorers and trading firms rising 2.28% and 1.54%, respectively.

Tokyu Fudosan Holdings jumped 4.4% to lead gainers on the Nikkei after the property developer agreed to sell its Tokyu Hands home interior store chain.

Drugmakers fell 0.48%, dragged by Eisai, which tumbled 9.06% after a Japanese government panel said that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by the Japanese company and Biogen Inc.

Astellas Pharma slipped 0.19%, while Takeda Pharmaceutical edged up 0.58%. (Editing by Devika Syamnath)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTELLAS PHARMA INC. -0.74% 2021 Delayed Quote.8.05%
BIOGEN INC. 0.97% 206.2 Delayed Quote.-14.05%
EISAI CO., LTD. 0.89% 5319 Delayed Quote.-18.56%
LONDON BRENT OIL 1.52% 119.2 Delayed Quote.46.84%
NIKKEI 225 0.66% 26781.68 Real-time Quote.-7.60%
S&P 500 2.47% 4158.24 Real-time Quote.-14.86%
TAKEDA PHARMACEUTICAL COMPANY LIMITED -0.48% 3744 Delayed Quote.19.35%
TOKAI CORP. 0.60% 1674 Delayed Quote.-15.24%
TOKYU FUDOSAN HOLDINGS CORPORATION -0.44% 680 Delayed Quote.5.75%
TOPIX INDEX 0.52% 1887.3 Delayed Quote.-5.76%
WTI 0.94% 115.083 Delayed Quote.46.90%
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
05/27TAKEDA PHARMACEUTICAL : and Seagen to Highlight ADCETRIS Combination Data
PU
05/26Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Signifi..
BU
05/12Japan Index Ends in Red; Toyota Clocks Record-High FY22 Attributable Income but Project..
MT
05/11Takeda Pharmaceutical's FY22 Attributable Profit Falls 39%
MT
05/11GLOBAL MARKETS LIVE : Coinbase, Roblox, Apple, EA, Hasbro...
05/11TRANSCRIPT : Takeda Pharmaceutical Company Limited, Q4 2022 Earnings Call, May 11, 2022
CI
05/11TRANSCRIPT : Takeda Pharmaceutical Company Limited, 2022 Earnings Call, May 11, 2022
CI
05/11Takeda Pharmaceutical Posts Higher Profit, Revenue in Fiscal 2021
MT
05/11Takeda Pharmaceutical Posted Fourth-Quarter Net Loss
DJ
05/11Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
BU
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 490 B 27 461 M 27 461 M
Net income 2022 239 B 1 880 M 1 880 M
Net Debt 2022 3 299 B 25 954 M 25 954 M
P/E ratio 2022 24,5x
Yield 2022 4,81%
Capitalization 5 779 B 45 471 M 45 471 M
EV / Sales 2022 2,60x
EV / Sales 2023 2,40x
Nbr of Employees 47 099
Free-Float 97,2%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 3 744,00 JPY
Average target price 4 402,67 JPY
Spread / Average Target 17,6%
EPS Revisions
Managers and Directors
Christophe Weber Chief Operating & Corporate Officer
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED19.35%45 471
NOVO NORDISK A/S-3.80%1 677 391
JOHNSON & JOHNSON5.86%476 521
PFIZER, INC.-8.70%302 483
ELI LILLY AND COMPANY17.11%291 184
ROCHE HOLDING AG-13.00%281 098